A drug to treat low female sexual desire should be approved with strict measures in place to ensure patients are fully aware of its risks, the advisory panel said WASHINGTON – A drug to treat low female sexual desire should be approved with strict measures in place to ensure patients are fully aware of its risks, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. Eighteen panelists voted in favor of approving the drug with a risk management program.
Are you up for a challenge?
